Allergan Plc announced that struck a global development and commercialisation agreement with AstraZeneca Plc regarding investigational antibiotic combination ATM-AVI. The fixed-dose combination of aztreonam and avibactam will be studied as treatment for serious infections triggered by metallo βlactamase MBL-producing Gram-negative pathogens. The terms of the deal give Allergan commercialisation rights in the US and Canada, with AstraZeneca holding them in all other countries.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
+1.73% | +0.97% |
1st Jan change | Capi. | |
---|---|---|
+0.97% | 6.37TCr | |
+61.53% | 86TCr | |
+38.95% | 63TCr | |
-3.66% | 36TCr | |
+15.06% | 32TCr | |
+9.21% | 30TCr | |
+5.89% | 23TCr | |
+16.53% | 23TCr | |
+15.67% | 18TCr | |
+2.43% | 16TCr |
- Stock Market
- Equities
- AGN Stock
- News Allergan plc
- Allergan Plc, AstraZeneca Plc Ink Collaboration Deal for Anti-Infective ATM-AVI